AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28716796
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection then progressive exercise (≤6 sessions)
Trial: 28716796
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection then best practice advice (one session)
Trial: 26095263
Drug: Anti-VEGF injections
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF injections (control)
Trial: 17199546
Drug: Flurbiprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (100 mg daily for 10 days) with scaling and root planing (SRP) in smokers (Group 3)
Trial: 17199546
Drug: Flurbiprofen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (100 mg daily for 10 days) with scaling and root planing (SRP) in non-smokers (Group 1)
Trial: 11287757
Drug: Acute oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute oral protein load in type 2 DM patients without microalbuminuria (MA)
Trial: 11287757
Drug: Acute oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute oral protein load in healthy subjects
Trial: 11287757
Drug: Acute oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute oral protein load in type 2 DM patients with microalbuminuria (MA)
Trial: 8485790
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia and analgesia (lidocaine 2% with epinephrine 1:200,000, 20 ml over 30 min; morphine 0.10 mg.kg‐1 after catheter insertion and 0.05 to 0.10 mg.kg‐1 every 12 hr as needed)
Trial: 8485790
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia alone (nitrous oxide, oxygen, isoflurane, supplemented with intravenous fentanyl to a maximum of 10 micrograms.kg‐1)
Trial: 3101606
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ACNU and Futraful (FT)
Trial: 3101606
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ACNU and FT
Trial: 3101606
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MMC and FT
Trial: 3101606
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ADM and FT
Trial: 1095794
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 to 1,600 mg daily)
Trial: 1095794
Drug: Aspirin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3 to 6 gm daily)
Trial: 31219558
Drug: Transdermal testosterone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone, 300 μg daily for 24 weeks
Trial: 31219558
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch for 24 weeks
Trial: 15553595
Drug: Prostaglandin E1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1, 40 microg infused twice daily for 28 days (group A)
Trial: 8446852
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) therapy for 6 to 24 months
Trial: 28985263
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg daily for 15 weeks
Trial: 20502296
Drug: Foley balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley balloon inflated to 30 mL
Trial: 20502296
Drug: Foley balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley balloon inflated to 60 mL
Trial: 17823963
Drug: Caffeine-free solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine-free solution (control)
Trial: 12471278
Drug: Droperidol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (20 mg/kg)
Trial: 2254769
Drug: Self-administered diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered diet history questionnaire
Trial: 140786
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide lotion
Trial: 140786
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A acid cream
Trial: 29112488
Drug: RIBSP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIBSP vaccine
Trial: 29112488
Drug: VAXIGRIP® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAXIGRIP® vaccine
Trial: 30442437
Drug: l-carnitine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine administration (1000mg of oral liquid l-carnitine once daily for 8 weeks)
Trial: 30442437
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no l-carnitine administration)
Trial: 30442437
Drug: l-carnitine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine administration
Trial: 27598802
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months initial chemotherapy (CT)
Trial: 27598802
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months initial chemotherapy (CT)
Trial: 27598802
Drug: No initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No initial chemotherapy (CT)
Trial: 11926556
Drug: Lanreotide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 0.5 mg
Trial: 9790077
Drug: Polyacrylonitrile (AN69)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyacrylonitrile (AN69) membrane plus subcutaneous EPO after HD
Trial: 9790077
Drug: Cuprophan membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuprophan membrane plus subcutaneous EPO after HD
Trial: 9790077
Drug: AN69 membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AN69 membrane plus subcutaneous EPO after HD plus intravenous EPO immediately before HD
Trial: 9790077
Drug: Cuprophan membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuprophan membrane plus subcutaneous EPO after HD plus intravenous EPO immediately before HD
Trial: 2116156
Drug: infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of propofol
Trial: 28074795
Drug: Grape Seed
RxNorm normalized name: grape seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape Seed Extract (GSE) 100 mg every 6 hours orally, 24 hours before operation
Trial: 28074795
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 25 mg/kg through CPB during surgery
Trial: 9688727
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of estrogen and progesterone therapy
Trial: 9688727
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone replacement therapy (No HRT)
Trial: 1681781
Drug: naltrexone hydrochloride
RxNorm normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naltrexone hydrochloride (50 mg/day)
Trial: 1681781
Drug: propoxyphene hydrochloride
RxNorm normalized name: Propoxyphene Hydrochloride
DrugBank: Dextropropoxyphene (DB00647)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propoxyphene hydrochloride (260 mg/day)
Trial: 31005396
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of intravenous ketorolac plus oxygen at 15 l/min through a non‐rebreather mask (NRB)
Trial: 31005396
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of intravenous ketorolac plus 7 l/min of oxygen through a 60% venturi mask
Trial: 31005396
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of intravenous ketorolac plus 4 l/min of oxygen through a nasal cannula
Trial: 31005396
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of intravenous ketorolac and room air
Trial: 24378381
Drug: Symax™ implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symax™ implant
Trial: 21604858
Drug: Institutional adjunctive
RxNorm normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Institutional adjunctive instruction condition
Trial: 21604858
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (no institutional adjunctive instruction)
Trial: 18703936
Drug: Quetiapine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine plus fluoxetine
Trial: 15714986
Drug: 5-alpha reductase
RxNorm normalized name: 5-alpha reductase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-alpha reductase inhibitor
Trial: 12595861
Drug: Abciximab (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abciximab (0.125 mg/kg) administered twice at 10-minute intervals with UFH (70 U/kg)
Trial: 12595861
Drug: Abciximab (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abciximab (0.125 mg/kg) administered twice at 10-minute intervals with dalteparin (60 IU/kg)
Trial: 12595861
Drug: Receptor occupancy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receptor occupancy assay and PAC1 binding assay
Trial: 1586385
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after overnight fast
Trial: 1586385
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after a light breakfast
Trial: 1586385
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days after a heavy breakfast
Trial: 1586385
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg erythromycin acistrate enteric coated tablets b.i.d. for 4 days (steady state)
Trial: 3702224
Drug: 0.55 to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.55 to 0.60 g protein/kg/day
Trial: 27680597
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of gabapentin and oxybutynin
Trial: 22682768
Drug: Mifepristone-misoprostol (n=220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone-misoprostol (n=220) - 200mg mifepristone on day 1 and 800 μg buccal misoprostol followed by placebo 3 hours later on day 2
Trial: 22682768
Drug: Misoprostol-only (n=221)
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol-only (n=221) - placebo on day 1 and 1600 μg of misoprostol (2 doses of 800 μg, given 3 hours apart) on day 2
Trial: 16213288
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) plus 1 g/d Mycophenolate mofetil (MMF)
Trial: 16213288
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) plus 2 g/d Mycophenolate mofetil (MMF)
Trial: 12236848
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort extract (255-285 mg, 900 micro g hypericin content)
Trial: 6781808
Drug: Methadone 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 15 mg . HCl
Trial: 27405619
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (LC) 750 mg/day, titrated up to 2250 mg/day
Trial: 27405619
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (CC) 3 g/day, titrated to achieve serum P levels of 3.5-6.0 mg/dL
Trial: 21359925
Drug: No acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No acupuncture treatment (Group C)
Trial: 19699111
Drug: Clofazimine 100
RxNorm normalized name: clofazimine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine 100 mg daily for 30 days, then 100 mg every other day
Trial: 19699111
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg 3 times daily
Trial: 19699111
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 pill 2 times daily
Trial: 7799341
Drug: D-penicillamine (intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine (intermittent treatment, every Monday, Wednesday, and Friday)
Trial: 7799341
Drug: D-penicillamine (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine (daily treatment)
Trial: 7799341
Drug: Both daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both daily and intermittent D-penicillamine treatments
Trial: 31454502
Drug: Lidocaine (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.8 mL, 36 mg lidocaine HCl and 0.0225 mg epinephrine)
Trial: 31454502
Drug: Tramadol (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (1.8 mL, 50 mg tramadol HCl and 0.0225 mg epinephrine diluted to 1.8 mL by distilled water)
Trial: 25072444
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy (adefovir 10 mg/d)
Trial: 23632053
Drug: PIL approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIL approach (80 mg methylprednisolone)
Trial: 23632053
Drug: MIL approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIL approach (80 mg methylprednisolone)
Trial: 16174713
Drug: Kisspeptin-54 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kisspeptin-54 infusion (4 pmol/kg x min)
Trial: 8324915
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (0.9%)
Trial: 8902860
Drug: Nebulized terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized terbutaline (2 ml solution diluted with 2 ml 0.9% saline for inhalation over 10 minutes)
Trial: 8902860
Drug: Injected epinephrine
RxNorm normalized name: epinephrine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected epinephrine (0.01 ml/kg of 1:1000 epinephrine, maximum 0.3 ml, subcutaneous injection)
Trial: 1867917
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with 400 mg cimetidine
Trial: 1867917
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy with cimetidine
Trial: 30633334
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training (PRT) 3 times per week for 50 weeks (20 weeks supervised, 30 weeks self-administered)
Trial: 15018291
Drug: Fludrocortisone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (0.3 mg orally 7 hours prior to landing)
Trial: 9716055
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (fourth course of FE120C, followed by radiation therapy and 2 years of tamoxifen)
Trial: 9716055
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (identical treatment but with an additional high-dose regimen and peripheral-blood progenitor-cell support after the fourth FE120C course)
Trial: 7984328
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon beta
Trial: 2721109
Drug: 337.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 337.5 mg/day propafenone
Trial: 2721109
Drug: 450 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg/day propafenone
Trial: 2721109
Drug: 675 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 675 mg/day propafenone
Trial: 2721109
Drug: 900 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg/day propafenone
Trial: 127471
Drug: Ro 6-0787
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 6-0787 combined with penicillin therapy
Trial: 127471
Drug: Combined Ro
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Ro 6-0787-penicillin treatment
Trial: 25923852
Drug: d-cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-cycloserine (50 mg daily)
Trial: 25923852
Drug: d-cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-cycloserine (50 mg weekly)
Trial: 21305238
Drug: Back school
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back school + exercise + physical treatment modalities
Trial: 21305238
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + physical treatment modalities
Trial: 21167689
Drug: Enriched supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched supportive therapy (EST)
Trial: 27684809
Drug: Glucose 75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 75% solution
Trial: 24158271
Drug: Deep brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep brain stimulation (DBS) combined with best medical therapy (BMT)
Trial: 17210383
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical therapy (BMT) alone
Trial: 16291717
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive (ethinyl estradiol 35 microg and varying doses of norgestimate: 0.18, 0.215, and 0.25 mg)
Trial: 16291717
Drug: No triphasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No triphasic oral contraceptive (control)
Trial: 11896479
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg phentolamine + 6 mg apomorphine
Trial: 11896479
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg phentolamine + 150 mg papaverine
Trial: 11896479
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg phentolamine + 6 mg apomorphine + 150 mg papaverine
Trial: 7650334
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha therapy (360‐700 MU/square meter of body surface, 2 or 3 times weekly for 12 to 24 weeks)
Trial: 2516669
Drug: R/5 (rifampicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R/5 (rifampicin, streptomycin, isoniazid, and pyrazinamide daily for 2 months, followed by streptomycin, isoniazid, and pyrazinamide twice weekly for 3 months)
Trial: 2516669
Drug: R/7 (rifampicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R/7 (rifampicin, streptomycin, isoniazid, and pyrazinamide daily for 2 months, followed by streptomycin, isoniazid, and pyrazinamide twice weekly for 5 months)
Trial: 2516669
Drug: Initial drug
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial drug resistance to streptomycin or isoniazid or both
Trial: 5023913
Drug: Sterile fusidic
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile fusidic acid gel introduced into the cavity on one occasion only
Trial: 5023913
Drug: Daily superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily superficial dressings impregnated with sodium fusidate ointment
Trial: 31858912
Drug: NSAIDs (Naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (Naproxen 1 gm/day or Etoricoxib 120 mg/day)
Trial: 30639273
Drug: Sequential combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combination training (SEQ)
Trial: 28459931
Drug: Daily calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily calorie restriction (75% of energy needs every day)
Trial: 28459931
Drug: Daily calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily calorie restriction
Trial: 21716078
Drug: non-HBV-active drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-HBV-active drugs